Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/57041
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYasar, H.A.-
dc.contributor.authorAktas, B.Y.-
dc.contributor.authorUcar, G.-
dc.contributor.authorGoksu, S.S.-
dc.contributor.authorBilgetekin, I.-
dc.contributor.authorCakar, B.-
dc.contributor.authorSakin, A.-
dc.contributor.authorAtes, Ozturk-
dc.contributor.authorBasoglu, Tugba-
dc.contributor.authorArslan, Cagatay-
dc.contributor.authorDemiray, Atike Gokcen-
dc.contributor.authorPaydas, Semra-
dc.contributor.authorCicin, Irfan-
dc.contributor.authorSendur, Mehmet Ali Nahit-
dc.contributor.authorKaradurmus, Nuri-
dc.contributor.authorKosku, Hakan-
dc.contributor.authorUner, Aytuğ-
dc.contributor.authorYumuk, Perran Fulden-
dc.contributor.authorUtkan, Gungor-
dc.contributor.authorKefeli, Umut-
dc.contributor.authorTanriverdi, Ozgur-
dc.contributor.authorCinkir, Havva-
dc.contributor.authorGumusay, Ozge-
dc.contributor.authorTurhal, Nazım Serdal-
dc.contributor.authorMenekse, Serkan-
dc.contributor.authorKut, Engin-
dc.contributor.authorBeypinar, Ismail-
dc.contributor.authorSakalar, Teoman-
dc.contributor.authorDemir, Hacer-
dc.contributor.authorYekeduz, Emre-
dc.contributor.authorKilickap, Saadettin-
dc.contributor.authorErman, Mustafa-
dc.contributor.authorUrun, Yuksel-
dc.date.accessioned2024-05-06T16:25:27Z-
dc.date.available2024-05-06T16:25:27Z-
dc.date.issued2024-
dc.identifier.issn1558-7673-
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2024.102077-
dc.identifier.urihttps://hdl.handle.net/11499/57041-
dc.description.abstractIntroduction: Adrenocortical carcinoma (ACC) is a rare yet highly malignant tumor associated with significant morbidity and mortality. This study aims to delineate the clinical features, survival patterns, and treatment modalities of ACC, providing insights into the disease's prognosis. Materials and Methods: A retrospective analysis of 157 ACC patients was performed to assess treatment methodologies, demographic patterns, pathological and clinical attributes, and laboratory results. The data were extracted from the hospital's database. Survival analyses were conducted using the Kaplan–Meier method, with univariate and multivariate analyses being performed through the log-rank test and Cox regression analyses. Results: The median age was 45, and 89.4% had symptoms at the time of diagnosis. The median tumor size was 12 cm. A total of 117 (79.6%) patients underwent surgery. A positive surgical border was detected in 26 (24.1%) patients. Adjuvant therapy was administered to 44.4% of patients. The median overall survival for the entire cohort was 44.3 months. Median OS was found to be 87.3 months (95% confidence interval [CI] 74.4-100.2) in stage 2, 25.8 (95% CI 6.5-45.1) months in stage 3, and 13.3 (95% CI 7.0-19.6) months in stage 4 disease. Cox regression analysis identified age, Ki67 value, Eastern Cooperative Oncology Group performance status, and hormonal activity as significant factors associated with survival in patients with nonmetastatic disease. In metastatic disease, only patients who underwent surgery exhibited significantly improved overall survival in univariate analyses. Conclusion: ACC is an uncommon tumor with a generally poor prognosis. Understanding the defining prognostic factors in both localized and metastatic diseases is vital. This study underscores age, Ki67 value, Eastern Cooperative Oncology Group performance status, and hormonal activity as key prognostic determinants for localized disease, offering critical insights into the complexities of ACC management and potential avenues for targeted therapeutic interventions. © 2024 Elsevier Inc.en_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvant therapy; Adrenocortical carcinoma; Mitotane; Neutrophil-lymphocyte ratio; Prognostic factorsen_US
dc.titleAdrenocortical cancer in the real world: A comprehensive analysis of clinical features and management from the Turkish Oncology Group (TOG)en_US
dc.typeArticleen_US
dc.identifier.volume22en_US
dc.identifier.issue3en_US
dc.departmentPamukkale Universityen_US
dc.identifier.doi10.1016/j.clgc.2024.102077-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57212386393-
dc.authorscopusid57207692951-
dc.authorscopusid57210847274-
dc.authorscopusid23018424300-
dc.authorscopusid57087082900-
dc.authorscopusid24402531400-
dc.authorscopusid55293011200-
dc.identifier.scopus2-s2.0-85190252782en_US
dc.identifier.wosWOS:001233240400001en_US
dc.institutionauthor-
item.languageiso639-1en-
item.openairetypeArticle-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

8
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.